Envestnet Portfolio Solutions
ITCI

Envestnet Portfolio Solutions’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Envestnet Portfolio Solutions’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-4,896
Closed -$409K – 1808
2024
Q4 		$409K Buy
4,896
+8
+0.2% +$657 ﹤0.01% 1336
2024
Q3 		$358K Buy
4,888
+771
+19% +$57.9K ﹤0.01% 1359
2024
Q2 		$282K Sell
4,117
-401
-9% -$27.8K ﹤0.01% 1411
2024
Q1 		$313K Sell
4,518
-245
-5% -$16.8K ﹤0.01% 1335
2023
Q4 		$341K Buy
4,763
+2
+0% +$115 ﹤0.01% 1230
2023
Q3 		$248K Buy
+4,761
New +$277K ﹤0.01% 1326

Other funds holding ITCI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Envestnet Portfolio Solutions's ITCI Position: Q1 2025 in Review

Envestnet Portfolio Solutions sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 4,896 shares — an estimated $409K sold.

Envestnet Portfolio Solutions first reported a position in ITCI in Q3 2023 and held it in 6 quarters. The position peaked at $409K in Q4 2024. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

  • Envestnet Portfolio Solutions reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
  • Envestnet Portfolio Solutions sold 4,896 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $409K.
  • Envestnet Portfolio Solutions first reported a position in Intra-Cellular Therapies Inc. in Q3 2023 and held it in 6 quarters.
  • Envestnet Portfolio Solutions's Intra-Cellular Therapies Inc. position peaked at $409K in Q4 2024.
  • 395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on Envestnet Portfolio Solutions's 13F filing for Q1 2025, filed 21 Apr 2025.